---
title: "Trulicity (dulaglutide), all indications: Specific populations questions"
description: "Specific populations questions on Trulicity (dulaglutide) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pregnancy and breastfeeding. Questions: Can Trulicity be used during pregnancy? Can Trulicity be used while breastfeeding? Is Trulicity safe and effective for adults 65 and older? Does Trulicity need a dose adjustment for kidney impairment? 2 further questions follow. 6 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/trulicity/specific-populations"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Trulicity (dulaglutide), all indications: Specific populations questions

Manufacturer: Eli Lilly and Company  
Prescribing information: [Trulicity](https://uspl.lilly.com/trulicity/trulicity.html#pi)  
Indication pages: [Type 2 diabetes](https://www.evicenter.com/medical-information/trulicity--type-2-diabetes)

## Pregnancy and breastfeeding

<a id="trulicity-pregnancy"></a>

### Can Trulicity be used during pregnancy?

> “Limited data with TRULICITY in pregnant women are not sufficient to determine a drug-associated risk for major birth defects and miscarriage. There are clinical considerations regarding the risks of poorly controlled diabetes in pregnancy [see Clinical Considerations]. Based on animal reproduction studies, there may be risks to the fetus from exposure to dulaglutide during pregnancy. TRULICITY should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Limited%20data%20with%20TRULICITY%20in,potential%20risk%20to%20the%20fetus.)

> “Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Poorly%20controlled%20diabetes%20in%20pregnancy%20increases,defects%2C%20stillbirth%2C%20and%20macrosomia%2Drelated%20morbidity.)

<a id="trulicity-breastfeeding"></a>

### Can Trulicity be used while breastfeeding?

> “There are no data on the presence of dulaglutide in human milk, the effects on the breastfed infant, or the effects on milk production. The presence of dulaglutide in milk of treated lactating animals was not determined. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for TRULICITY and any potential adverse effects on the breastfed infant from TRULICITY or from the underlying maternal condition.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=There%20are%20no%20data%20on,from%20the%20underlying%20maternal%20condition.)

## Specific populations

<a id="trulicity-older-adults"></a>

### Is Trulicity safe and effective for adults 65 and older?

> “In the adult glycemic control trials [see Clinical Studies (14.2, 14.3)], 620 (19%) of TRULICITY-treated patients were 65 years of age or older and 65 (2%) of TRULICITY-treated patients were 75 years of age or older at baseline. In the TRULICITY 1.5 mg treatment arm of the REWIND trial (cardiovascular outcomes trial in adults with type 2 diabetes mellitus and cardiovascular disease or multiple cardiovascular risk factors) [see Clinical Studies (14.5)], 2,619 (53%) patients were 65 years of age or older, and 484 (10%) patients were 75 years of age or older at baseline.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=In%20the%20adult%20glycemic%20control,patients%20were%2075%20years%20of%20age%20or%20older%20at%20baseline.)

> “No overall differences in safety or effectiveness for TRULICITY have been observed between patients 65 years of age and older and younger adult patients.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=No%20overall%20differences%20in%20safety,older%20and%20younger%20adult%20patients.)

> “Yes. In pooled study results, there were no overall differences in safety or efficacy between older and younger patients but greater sensitivity in some older individuals cannot be ruled out.<sup>1</sup>
>
> 620 (18.6%) Trulicity-treated patients were 65 years of age or over
> 65 (1.9%) Trulicity-treated patients were 75 years of age or over”

Source: [TRULICITY: Resources for HCPs – Videos & FAQs, captured 2026-11-13](https://trulicity.lilly.com/hcp/resources#faq:~:text=Yes.%20In%20pooled%20study%20results%2C,75%20years%20of%20age%20or%20over)

On the page, select: Did patients on Trulicity lose weight in clinical trials?

Note: The last passage is from the resources page of the Trulicity HCP site, which restates earlier label wording; the first two passages are from section 8.5 of the current Prescribing Information.

<a id="trulicity-kidney-dosing"></a>

### Does Trulicity need a dose adjustment for kidney impairment?

> “TRULICITY has been studied in patients with varying degrees of renal function, including a dedicated clinical trial in patients with moderate to severe chronic kidney disease. No overall differences in safety or effectiveness were observed in these studies according to renal function [see Clinical Studies (14.2, 14.3, 14.4)].”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=TRULICITY%20has%20been%20studied%20in,Clinical%20Studies%20%2814.2%2C%2014.3%2C%2014.4%29%5D.)

> “No dose adjustment is recommended in patients with renal impairment including end-stage renal disease (ESRD). Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions. Use TRULICITY with caution in patients with ESRD [see Warning and Precautions (5.5), Clinical Pharmacology (12.3)].”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=No%20dose%20adjustment%20is%20recommended,Precautions%20%285.5%29%2C%20Clinical%20Pharmacology%20%2812.3%29%5D.)

<a id="trulicity-liver-dosing"></a>

### Can Trulicity be used in patients with liver impairment?

> “In a clinical pharmacology study in patients with varying degrees of hepatic impairment, no clinically relevant change in dulaglutide PK was observed [see Clinical Pharmacology (12.3)]. However, there is limited clinical experience in patients with mild, moderate, or severe hepatic impairment; therefore, use TRULICITY with caution in these patient populations.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=In%20a%20clinical%20pharmacology%20study%20in%20patients%20with%20varying,caution%20in%20these%20patient%20populations.)

<a id="trulicity-overdose"></a>

### What happens after a Trulicity overdose?

> “Overdoses have been reported in clinical studies. Effects associated with these overdoses were primarily mild or moderate gastrointestinal events (e.g., nausea, vomiting) and non-severe hypoglycemia. In the event of overdose, consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations. Initiate appropriate supportive care (including frequent plasma glucose monitoring) according to the patient's clinical signs and symptoms.”

Source: [TRULICITY: Prescribing information, captured 2026-11-13](https://uspl.lilly.com/trulicity/trulicity.html#pi:~:text=Overdoses%20have%20been%20reported%20in,patient%27s%20clinical%20signs%20and%20symptoms.)

## Related pages
- [Medical information: Trulicity (dulaglutide): All indications](https://www.evicenter.com/medical-information/trulicity)
- [Indication](https://www.evicenter.com/medical-information/trulicity/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/trulicity/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/trulicity/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/trulicity/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/trulicity/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/trulicity/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/trulicity/access-and-coverage)
